Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated …
MM Patnaik, MM Timm, R Vallapureddy, TL Lasho… - Blood cancer …, 2017 - nature.com
MM Patnaik, MM Timm, R Vallapureddy, TL Lasho, RP Ketterling, N Gangat, M Shi, A Tefferi…
Blood cancer journal, 2017•nature.comChronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome/
myeloproliferative neoplasm (MDS/MPN) overlap syndrome characterized by peripheral
blood monocytosis (absolute monocyte count/AMC⩾ 1× 10 (9)/l,⩾ 10% of the total white
blood cell count) and an inherent risk for leukemic transformation. 1, 2 Monocytosis,
however, is not pathognomic for CMML and can be associated with reactive and clonal
processes, including MPN such as polycythemia Vera (PV) and primary
myeloproliferative neoplasm (MDS/MPN) overlap syndrome characterized by peripheral
blood monocytosis (absolute monocyte count/AMC⩾ 1× 10 (9)/l,⩾ 10% of the total white
blood cell count) and an inherent risk for leukemic transformation. 1, 2 Monocytosis,
however, is not pathognomic for CMML and can be associated with reactive and clonal
processes, including MPN such as polycythemia Vera (PV) and primary
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndrome characterized by peripheral blood monocytosis (absolute monocyte count/AMC⩾ 1× 10 (9)/l,⩾ 10% of the total white blood cell count) and an inherent risk for leukemic transformation. 1, 2 Monocytosis, however, is not pathognomic for CMML and can be associated with reactive and clonal processes, including MPN such as polycythemia Vera (PV) and primary
nature.com